State Street Corp increased its stake in American Express Company (AXP) by 1.3% in the fourth quarter, bringing its total holdings to $10.90 billion, representing 4.29% of the company. Other institutional investors also boosted their holdings in AXP during the third quarter. Analysts have provided varied price targets and ratings, with the stock currently holding an average "Hold" rating and a consensus target price of $359.05.

State Street Corp increased its stake in BlackRock (NYSE:BLK) by 0.5% during the fourth quarter, acquiring an additional 33,752 shares. Several other institutional investors, including Legal & General Group Plc, Ontario Teachers Pension Plan Board, and PNC Financial Services Group Inc., also adjusted their holdings in BlackRock. The article also touches upon BlackRock's recent financial performance, dividend announcement, analyst ratings, and insider trading activity, alongside news regarding its private-credit funds and digital asset endeavors.

Van ECK Associates Corp significantly increased its stake in Otis Worldwide Corporation by 97.9% in the fourth quarter, now holding 4.0 million shares valued at $349.6 million. Despite mixed quarterly results where EPS and revenue missed estimates, Otis Worldwide raised its quarterly dividend. The company currently has a consensus "Hold" rating from analysts with an average price target of $97.58.

Van ECK Associates Corp increased its stake in The Clorox Company by 15.7% in the fourth quarter, purchasing 426,433 shares to reach a total of 3.14 million shares valued at $316.2 million. Clorox reported better-than-expected quarterly earnings of $1.64 EPS, and maintained its FY2026 EPS guidance, but sentiment remains cautious with a "Reduce" consensus rating from analysts. Several other institutional investors also increased their holdings in Clorox during recent quarters.

Praesidium Investment Management Company LLC reduced its stake in Transdigm Group Incorporated (NYSE:TDG) by 16.9% in the fourth quarter, selling 5,312 shares and retaining 26,200 shares worth $34.8 million. Despite this, institutional ownership remains high at 95.78%, and analysts generally maintain a "Moderate Buy" rating with an average target price of $1,524.18. The company recently exceeded earnings per share and revenue estimates for the quarter, though several insiders have sold shares.

State Street Corp increased its stake in International Business Machines Corporation (IBM) by 1.0% in the fourth quarter, purchasing an additional 518,321 shares. This makes IBM the 27th biggest holding in State Street Corp's portfolio, with the institutional investor owning 5.88% of the company. Other institutional investors, including Norges Bank and Capital World Investors, also adjusted their positions in IBM during the same period.

State Street Corp increased its stake in Intuit Inc. by 1.4% during the fourth quarter, purchasing an additional 180,069 shares. The institutional investor now owns over 13 million shares of Intuit, valued at approximately $8.65 billion. Several other hedge funds have also adjusted their holdings in Intuit, with the company facing both positive and negative sentiment from recent news, including a senior notes offering, strong online business growth, insider selling, and investigations into its pricing practices.

Fifth Third Bancorp (FITB) is currently trading below its estimated fair value, with strong forecasted earnings growth and a reliable dividend. The company is actively restructuring its capital and expanding digital offerings, including moving its stock listing to the NYSE and introducing new business banking features and fraud protection tools. Despite significant insider selling over the past three months and recent share dilution, analysts generally hold a constructive view on the stock, anticipating benefits from the Comerica integration and strategic expansion.

State Street Corp significantly increased its stake in Amgen Inc. by 4.4% in the fourth quarter, bringing its total holdings to over 30.5 million shares valued at approximately $10.01 billion. Other institutional investors like Robeco Institutional Asset Management B.V. and Fideuram Intesa Sanpaolo Private Banking S.P.A. also raised their positions, with institutional investors and hedge funds now owning 76.50% of Amgen's stock. Recent analyst ratings suggest a "Hold" consensus for Amgen, with an average target price of $354.12, while positive news regarding its pipeline and cardiovascular study is balanced by regulatory uncertainty surrounding its drug Tavneos.

This page provides access to VEON Ltd.'s SEC filings, including 10-K annual reports, 10-Q quarterly reports, and 8-K material events, along with AI-generated summaries and sentiment analysis for each. Recent filings detail events such as Kyivstar investor updates, sale-and-leaseback transactions, acquisitions, debt profiles, and insider stock sales. The most recent filing as of this page was October 21, 2025.